A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 577 participants.

Also called NCT01621178

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 577 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01621178
  • EudraCT 2012-000829-44
Other papers using this trial's data
  • Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial The lancet. Diabetes & endocrinology, 2018-08 DOI, PubMed 29910024

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Hungary, Mexico, Poland, Romania, South Africa, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01621178. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2016-06 (actual). Results posted on 2017-07-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
Acronym
AWARD-7
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Insulin lispro
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01621178
Content hash
bc227bb26e6e25b1d77de11b004426a71e775825ae44e46b97c8d23439a8b78d